DGKZ

Across TCGA pan-cancer cohorts, DGKZ Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated DGKZ data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DGKZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DGKZ expression acts as an unfavorable survival marker.

LUAD, STAD, and BRCA are the cancer types where DGKZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.083	0.788	<.001	32	view →
STAD	OS	Median	II,III,IV	0.350	0.679	<.001	24	view →
BRCA	DFS	Median	III,IV	0.019	0.881	<.001	22	view →
MESO	OS	Median	III,IV	0.069	0.580	<.001	12	view →
LIHC	DFS	Median	All	0.096	0.543	.028	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

DGKZ–LUAD (OS)

Open the LUAD breakdown →